Available since November 2019, EGRIFTA SV™ has the following key features versus EGRIFTA^®:

• Lower injection volume (0.35 mL vs 2 mL);
• Room temperature storage (between 68°F to 77°F).

Given the commercial availability of EGRIFTA SV™ since November 2019 and its key features, EGRIFTA^® will no longer be manufactured as of June 15ᵗʰ, 2020.

Most patients have been successfully transitioned to EGRIFTA SV™, if you are still receiving EGRIFTA^® you can contact your healthcare provider or THERA patient support^® (at 1-833-23THERA or 1-833-238-4372, Mon-Fri 8:30AM-8:00PM ET) to understand your options.

The full Prescribing Information, Patient Information, and Instructions for Use for EGRIFTA SV™ can be found on www.egriftasv.com.

The full Prescribing Information, Patient Information, and Instructions for Use for EGRIFTA^® can be found on www.egrifta.com.